-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Eli Lilly and Evotec SE jointly announced that the two companies have entered into a drug discovery collaboration in the field of metabolic diseases, focusing on kidney disease and diabetes
The collaboration will leverage Evotec's experience and expertise in metabolic disease, as well as its unique and extensive renal disease patient database, integrated data-driven drug discovery and development platform, to identify and validate promising new targets for therapeutic intervention
Evotec will be responsible for discovering potential drug candidates for diabetes and chronic kidney disease from targets identified by Eli Lilly or Evotec
The partnership will initially run for three years